As regards to RCC, in particular, in advanced and/or metastatic forms, the first generation of mTOR inhibitors (temsirolimus and everolimus) is already in clinical use and has been showing some efficacy, particularly when combined with VEGF modulators. The gene discussed is MTOR; the disease is renal cell carcinoma.